Filing Flows › P3 Health Partners (PIII) › Stock forecast & fair value
P3 Health Partners (PIII) stock forecast and fair value
P3 Health Partners (PIII) trades at $4.00. 2 analysts' median price target is $18.00 (+350%), from $13.00 to $23.00. Across 13 valuation methods the middle fair value is $12.42 (+210%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $8.10 | $13.56 | $20.66 | +239% |
| EV/Sales vs peers, weighted | $9.10 | $13.12 | $16.50 | +228% |
| EV/Sales vs peers, growth & margin adjusted | $7.38 | $12.42 | $20.67 | +210% |
| Residual income | −$0.34 | −$0.34 | −$0.34 | -109% |
| Sum of the parts (segments × peer EV/Sales) | $8.34 | $13.95 | $21.24 | +249% |
| Sum of the parts, weighted (segments × weighted peer EV/Sales) | $9.36 | $13.50 | $16.98 | +238% |
| Analysts' price targets | $13.00 | $18.00 | $23.00 | +350% |
| Tangible book (asset value) | $0.00 | $0.00 | $0.00 | — |
| Survival-weighted value | $1.20 | $2.00 | $3.05 | -50% |
| Stage-weighted value (decline / turnaround) | $3.02 | $5.05 | $7.70 | +26% |
P3 Health Partners' latest quarter
P3 Health Partners, Q2 2026: revenue $386M (+9% year over year), operating margin 10.7%, net earnings $7.4M, operating cash flow −$61.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PIII stock?
The median of 2 analysts' 12-month targets is $18.00, +350% from $4.00; the range is $13.00 to $23.00. The average rating is none.
What is P3 Health Partners' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$0.34 and $18.00, with a middle value of $12.42 against a price of $4.00. Each method's assumptions are on the page.
Does P3 Health Partners usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is PIII stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.